Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19

The FDA has signed off Pardes Biosciences Inc's PRDS Investigational New Drug (IND) application for PBI-0451 for COVID-19.

  • Pending further engagement with FDA and other regulators, the Company anticipates initiating global Phase 2/3 studies of PBI-0451 in SARS-CoV-2 infected patients in mid-2022.
  • "The clearance of our IND for PBI-0451 enables us to proceed with the initiation of additional Phase 1 clinical trials for PBI-0451 in the U.S.," said Uri Lopatin, Chief Executive Officer. 
  • PB-0451 is currently under evaluation in a Phase 1 study in healthy volunteers in New Zealand evaluating the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses. 
  • Later this quarter, Pardes anticipates reporting data from this ongoing study at a scientific conference.
  • Price Action: PRDS shares are up 6.54% at $11.08 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!